Ovarian Cancer Clinical Trial

Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

Summary

Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

View Full Description

Full Description

This treatment protocol will serve as a mechanism to continue to provide ficlatuzumab to patient 0001-000412, who was previously enrolled under protocol P05538 and whom the investigator believes is deriving clinical benefit from ficlatuzumab treatment.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Per original P05538 protocol

Exclusion Criteria:

Per original P05538 protocol

Study is for people with:

Ovarian Cancer

Study ID:

NCT02090127

Recruitment Status:

No longer available

Sponsor:

AVEO Pharmaceuticals, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

START
San Antonio Texas, 78229, United States

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Study ID:

NCT02090127

Recruitment Status:

No longer available

Sponsor:


AVEO Pharmaceuticals, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider